AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8396092 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g single oral dose
Number of subjects: 143
Study 8396092 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg bid for seven days
Number of subjects: 143
Study 2418126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 RSV isolates
Number of subjects: 223
Study 2418126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 RSV isolates
Number of subjects: 223
Study 2418126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate character RSV isolates
Number of subjects: 223
Study 2418126 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired RSV isolates
Number of subjects: 223
Study 2418126 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV isolates from the 1981-1982 season
Number of subjects: 223
Study 30993773 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat stress (HEAT)
Number of subjects: 10
Study 30993773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical forearm compression (CUFF)
Number of subjects: 10
Study 30993773 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise (HGEX)
Number of subjects: 10
Study 29142136 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus maraviroc (MVC)
Number of subjects: 18
Study 29142136 — intervention group
Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 18
Study 29142136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MVC+ and MVC-)
Number of subjects: 18
Study 26872112 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus metformin
Number of subjects: 25
Study 26872112 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 25
Study 25284435 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CAIS
Number of subjects: 46
Study 25284435 — intervention group
Group type: COMPARATOR
Intervention: Typical (46,XY) men
Number of subjects: 46
Study 22828553 — intervention group
Group type: EXPERIMENTAL
Intervention: Asphyxiated newborns (Group I)
Number of subjects: 75
Study 22828553 — intervention group
Group type: COMPARATOR
Intervention: Control newborns (Group II)
Number of subjects: 75
Study 20819493 — intervention group
Group type: EXPERIMENTAL
Intervention: NDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml normal saline
Number of subjects: 68
Study 20819493 — intervention group
Group type: COMPARATOR
Intervention: cDDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml normal saline
Number of subjects: 68
Study 18062117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP)
Number of subjects: 58
Study 18062117 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 58
Study 18062117 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GCF MMP-8 levels between flurbiprofen and placebo groups after therapy
Number of subjects: 58
Study 15711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus vaccine administered at 2, 3, 9 months concurrently with BCG (n=20)
Number of subjects: 60
Study 15711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus vaccine administered at 3, 4, 9 months concurrently with BCG or other vaccines (n=20)
Number of subjects: 60
Study 15711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus vaccine administered at 0, 1, 6 months with no other coinciding vaccine (n=20)
Number of subjects: 60
Study 12009349 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.312 mg/day for 21 days per cycle during six cycles, plus chlormadinone acetate 2 mg/day for the last 5 days of each cycle)
Number of subjects: 30
Study 9718613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure force applied during distraction test
Number of subjects: 17
Study 9718613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure force applied during compression test
Number of subjects: 17
Study 9718613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure force applied during pressure on the apex sacralis
Number of subjects: 17
Study 9718613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure force registration
Number of subjects: 17
Study 9718613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-test reliability
Number of subjects: 17
Study 7667327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH, 0.65 + 0.35 g.kg‐1)
Number of subjects: 21
Study 7667327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ, 15 mg)
Number of subjects: 21
Study 7667327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ, 30 mg)
Number of subjects: 21
Study 7667327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7667327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ, 2 mg)
Number of subjects: 21
Study 2782734 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inhaled salbutamol (HDS), 4,000 micrograms daily
Number of subjects: 12
Study 2782734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose inhaled salbutamol (LDS), 800 micrograms daily
Number of subjects: 12
Study 2782734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PI)
Number of subjects: 12
Study 2782734 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inhaled salbutamol (HDS)
Number of subjects: 12
Study 809835 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 60
Study 809835 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 60
Study 31169883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 9737
Study 31169883 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione
Number of subjects: 9737
Study 31169883 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐hydroxyprogesterone
Number of subjects: 9737
Study 31169883 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA‐S
Number of subjects: 9737
Study 31169883 — intervention group
Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 9737
Study 29179724 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP intervention
Number of subjects: 676
Study 26434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Number of subjects: 0
Study 26434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction
Number of subjects: 0
Study 26434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning with reward-US
Number of subjects: 0
Study 26434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction with pain-US
Number of subjects: 0
Study 26434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning with pain-US and reward-US
Number of subjects: 0
Study 23139262 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin (50 mg/m² d1), ifosfamide (3 g/m²/day d1-2), cisplatin (75 mg/m² d3) + G-CSF every 3 weeks (arm A)
Number of subjects: 81
Study 23139262 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm B)
Number of subjects: 81
Study 23139262 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin, ifosfamide, cisplatin + G-CSF (arm A)
Number of subjects: 81
Study 22256637 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 320
Study 22256637 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong capsule
Number of subjects: 320
Study 22256637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 320
Study 22256637 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medication
Number of subjects: 320
Study 18438705 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg for 14 days)
Number of subjects: 206
Study 18438705 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg for 14 days)
Number of subjects: 206
Study 17069753 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT focused solely on panic disorder and agoraphobia
Number of subjects: 65
Study 17069753 — intervention group
Group type: COMPARATOR
Intervention: CBT that addressed panic disorder and comorbid conditions
Number of subjects: 65
Study 14679377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) diet with healthy eating advice (n=26, age 63.6+/‐9.4 y)
Number of subjects: 55
Study 14679377 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating dietary advice only (control group, n=29, age 61.8+/‐9 y)
Number of subjects: 55
Study 14679377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LGI diet and control diet)
Number of subjects: 55
Study 11476130 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day
Number of subjects: 54
Study 11476130 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg/day
Number of subjects: 54
Study 9597411 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine 20 g daily for 5 days
Number of subjects: 0
Study 9597411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8192458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) at 30 mg/kg/day for 10 days
Number of subjects: 263
Study 8192458 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMX-CL) at 40 mg/kg/day for 10 days
Number of subjects: 263
Study 8192458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE)
Number of subjects: 263
Study 8192458 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMX-CL)
Number of subjects: 263
Study 3285829 — intervention group
Group type: EXPERIMENTAL
Intervention: torasemide (20 mg i.v.)
Number of subjects: 8
Study 3285829 — intervention group
Group type: COMPARATOR
Intervention: furosemide (40 mg i.v.)
Number of subjects: 8
Study 3285829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 8
Study 30676813 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min cold shower after running exercise
Number of subjects: 10
Study 30676813 — intervention group
Group type: COMPARATOR
Intervention: No shower (control trial)
Number of subjects: 10
Study 28195544 — intervention group
Group type: EXPERIMENTAL
Intervention: New test statistics based on multinomial distributions
Number of subjects: 0
Study 28195544 — intervention group
Group type: COMPARATOR
Intervention: Cochran test
Number of subjects: 0
Study 26376926 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose trivalent subunit inactivated intramuscular vaccine
Number of subjects: 213
Study 22862902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight large-pore mesh with human fibrin glue (HFG)
Number of subjects: 80
Study 22862902 — intervention group
Group type: COMPARATOR
Intervention: Standard heavyweight small-pore mesh with human fibrin glue (HFG)
Number of subjects: 80
Study 21335509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis
Number of subjects: 29133
Study 21335509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis diagnosis
Number of subjects: 29133
Study 19432601 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support (companionship during labour)
Number of subjects: 585
Study 19432601 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 585
Study 16918614 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol ointment applied twice daily
Number of subjects: 0
Study 16918614 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 16918614 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 14726725 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study 14726725 — intervention group
Group type: COMPARATOR
Intervention: Emergency hospitalization
Number of subjects: 0
Study 11142582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 0.2 mg/kg/day for 6 months (group A)
Number of subjects: 13
Study 11142582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon 3 MU, three times a week for 6 months (group B)
Number of subjects: 13
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and antiplatelet agents
Number of subjects: 0
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (including warfarin sodium)
Number of subjects: 0
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (including timolol maleate, propranolol hydrochloride)
Number of subjects: 0
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (including captopril, ramipril)
Number of subjects: 0
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering (including simvastatin)
Number of subjects: 0
Study 9382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet studies
Number of subjects: 0
Study 9382659 — intervention group
Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 0
Study 8322563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2% and adrenaline 1:200,000 with crystalloid volume loading of 10 ml.kg-1 b.w.
Number of subjects: 20
Study 8322563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 20
Study 8322563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 1%
Number of subjects: 20
Study 2868656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg twice daily for 10 weeks)
Number of subjects: 30
Study 2868656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 10 weeks)
Number of subjects: 30
Study 30789581 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 12
Study 30789581 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 29986676 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and diabetes intervention program (PASOS)
Number of subjects: 600
Study 29986676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 600
Study 27427558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (3, 6, or 9 mg/d)
Number of subjects: 200
Study 27427558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 24255008 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 1.5ATA
Number of subjects: 61
Study 24255008 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2.0ATA
Number of subjects: 61
Study 24255008 — intervention group
Group type: COMPARATOR
Intervention: Surface air (sham)
Number of subjects: 61
Study 23301475 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking with vaccaria seed at Endocrine (CO18), Mammary Gland, etc., pressed 3 times daily for 1-2 min each time
Number of subjects: 107
Study 23301475 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 107
Study 23301475 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking
Number of subjects: 107
Study 20506356 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 176
Study 20506356 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 176
Study 18086500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby massage classes
Number of subjects: 65
Study 18086500 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 65
Study 16049131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 21
Study 16049131 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 21
Study 12621135 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 50
Study 12621135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12775187 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesic participants
Number of subjects: 0
Study 12775187 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 12775187 — intervention group
Group type: COMPARATOR
Intervention: College participants
Number of subjects: 0
Study 9652876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 2607
Study 9652876 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated with nifedipine)
Number of subjects: 2607
Study 7661158 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. and amoxicillin 1 g t.i.d. (OA)
Number of subjects: 60
Study 7661158 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d. plus tetracycline 500 mg t.i.d. (OAT)
Number of subjects: 60
Study 2508566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C (MMC) and tegafur (FT)
Number of subjects: 2477
Study 2508566 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection only
Number of subjects: 2477
Study 813585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate TIN
Number of subjects: 18
Study 813585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat TIN (Intralipid)
Number of subjects: 18
Study 813585 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 29635383 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg)
Number of subjects: 23
Study 29635383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28712185 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Group I)
Number of subjects: 86
Study 28712185 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) + Propofol (Group II)
Number of subjects: 86
Study 26647926 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT+PCM (test group)
Number of subjects: 20
Study 26647926 — intervention group
Group type: COMPARATOR
Intervention: CAF+PCM (control group)
Number of subjects: 20
Study 24012096 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (6 mL)
Number of subjects: 145
Study 24012096 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 145
Study 21794845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% AR‐12286 Ophthalmic Solution
Number of subjects: 89
Study 21794845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% AR‐12286 Ophthalmic Solution
Number of subjects: 89
Study 21794845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% AR‐12286 Ophthalmic Solution
Number of subjects: 89
Study 21794845 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 89
Study 19737493 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Dependence Scale (ADS)
Number of subjects: 3001
Study 19737493 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ADS and subscales derived from factor analyses
Number of subjects: 3001
Study 19737493 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item reduced ADS measure
Number of subjects: 3001
Study 19737493 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-item reduced ADS measure
Number of subjects: 3001
Study 16514567 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal (2 meals rich in protein)
Number of subjects: 8
Study 16514567 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (1 meal rich in carbohydrates)
Number of subjects: 8
Study 16514567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal (1 meal rich in fat)
Number of subjects: 8
Study 15484172 — intervention group
Group type: EXPERIMENTAL
Intervention: Managerial-based intervention involving changes in nurses' skill discretion and decision-making participation over six months.
Number of subjects: 0
Study 15484172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 10688085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 54
Study 10688085 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 54
Study 8996166 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct inhibitor of TS (ZD1694)
Number of subjects: 0
Study 8996166 — intervention group
Group type: COMPARATOR
Intervention: Indirect inhibitor (5-FU/LV)
Number of subjects: 0
Study 8440808 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide treatment
Number of subjects: 0
Study 8440808 — intervention group
Group type: COMPARATOR
Intervention: Reversed depressive symptoms
Number of subjects: 0
Study 29053933 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ellagic acid daily for 12 weeks
Number of subjects: 150
Study 29053933 — intervention group
Group type: COMPARATOR
Intervention: Placebo cellulose
Number of subjects: 150
Study 26689303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-directed hypnosis for 3 weeks
Number of subjects: 108
Study 26689303 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring control condition for 3 weeks
Number of subjects: 108
Study 26689303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) after initial treatment
Number of subjects: 108
Study 24716545 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-tailored facilitator-based intervention with three one-hour visits by a facilitator.
Number of subjects: 189
Study 24716545 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-tailored facilitator-based intervention.
Number of subjects: 189
Study 24716545 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control).
Number of subjects: 189
Study 22399019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 12 sessions, manualized
Number of subjects: 369
Study 22399019 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 369
Study 22399019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 369
Study 20223272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass air-polishing
Number of subjects: 50
Study 20223272 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate air-polishing
Number of subjects: 50